Investor Relations

Website Notice Block

Corporate Profile

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events
Investor Presentation
Quarterly Results

Press Releases

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

July 16, 2024

Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd.

MediWound Announces $25 Million Strategic Private Placement Financing

July 15, 2024

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it

View All Press Releases  ///